Literature DB >> 15903266

Transduction efficiency of pantropic retroviral vectors is controlled by the envelope plasmid to vector plasmid ratio.

Yong Chen1, William M Miller, Ashok Aiyar.   

Abstract

Pantropic retroviral vectors pseudotyped with vesicular stomatitis virus envelope G protein (VSV-G) are typically produced by transient transfection of the VSV-G expression plasmid because constitutive expression of VSV-G is cytotoxic. To produce pantropic vectors, the VSV-G expression plasmid and the vector plasmid are cotransfected into a packaging cell line, such as 293-gag-pol. Typically, the ratio of VSV-G plasmid to the vector plasmid ranges from 0.33 to 1.0. However, it is not clear that this range is optimal for vector production. In this study we have systematically examined the effect of the ratio of VSV-G plasmid (pVSV-G) to vector plasmid on vector production. For this, 293-gag-pol stable packaging cells were cotransfected with pVSV-G and an enhanced green fluorescent protein- (EGFP-) expressing retroviral vector plasmid (pLTR-EGFP) by use of lipofectamine. Vector was collected following transfection and used to transduce three target cell lines, namely, 3T3 fibroblasts, telomerase-immortalized human diploid fibroblasts (HDF), and the human hepatoma cell line HuH7. Transduction efficiency was evaluated for vectors produced at different pVSV-G:pLTR-EGFP ratios such that the total amount of plasmid transfected into 293-gag-pol cells was kept constant. Our results indicate that transduction efficiency is greatest when the pVSV-G:pLTR-EGFP ratio is substantially below 1.0. For 3T3 and HDF cells, the maximum transduction efficiency was obtained when a ratio of pVSV-G:pLTR-EGFP ranging from 0.053 to 0.2 was used for transfection. The relative magnitude of this effect was greater for lower transduction efficiencies in control cultures. For HuH7 cells, the beneficial effects were smaller than those observed when HDF or 3T3 cells were used. The difference in transduction efficiency for vector produced under various pVSV-G:pLTR-EGFP ratios was not due to differences in the proliferation of packaging cells or target cells. Further characterization showed that the amount of vector RNA relative to p30gag decreased as the ratio of pVSV-G:pLTR-EGFP increased. These results indicate that transduction efficiency increases with increasing levels of vector RNA as long as a minimally sufficient level of pantropic envelope protein is expressed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15903266      PMCID: PMC2913131          DOI: 10.1021/bp049865x

Source DB:  PubMed          Journal:  Biotechnol Prog        ISSN: 1520-6033


  25 in total

1.  RNA is a structural element in retrovirus particles.

Authors:  D Muriaux; J Mirro; D Harvin; A Rein
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

2.  Effects of stoichiometry of retroviral components on virus production.

Authors:  Melvyn W Yap; Susan M Kingsman; Alan J Kingsman
Journal:  J Gen Virol       Date:  2000-09       Impact factor: 3.891

3.  Efficient cell infection by Moloney murine leukemia virus-derived particles requires minimal amounts of envelope glycoprotein.

Authors:  E Bachrach; M Marin; M Pelegrin; G Karavanas; M Piechaczyk
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Susceptibility of cell populations to transduction by retroviral vectors.

Authors:  Simon Wotherspoon; Alla Dolnikov; Geoff Symonds; Robert Nordon
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

5.  Kinetic analyses of stability of simple and complex retroviral vectors.

Authors:  F Higashikawa; L Chang
Journal:  Virology       Date:  2001-02-01       Impact factor: 3.616

6.  Assembly of gag-beta-galactosidase proteins into retrovirus particles.

Authors:  T A Jones; G Blaug; M Hansen; E Barklis
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

7.  Maintenance of the Gag/Gag-Pol ratio is important for human immunodeficiency virus type 1 RNA dimerization and viral infectivity.

Authors:  M Shehu-Xhilaga; S M Crowe; J Mak
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

8.  Efficient gene transfer of VSV-G pseudotyped retroviral vector to human brain tumor.

Authors:  H Lee; J J Song; E Kim; C O Yun; J Choi; B Lee; J Kim; J W Chang; J H Kim
Journal:  Gene Ther       Date:  2001-02       Impact factor: 5.250

9.  High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter.

Authors:  Christophe Demaison; Kathryn Parsley; Gaby Brouns; Michaela Scherr; Karin Battmer; Christine Kinnon; Manuel Grez; Adrian J Thrasher
Journal:  Hum Gene Ther       Date:  2002-05-01       Impact factor: 5.695

10.  Murine sarcoma and leukemia viruses: assay using clonal lines of contact-inhibited mouse cells.

Authors:  J L Jainchill; S A Aaronson; G J Todaro
Journal:  J Virol       Date:  1969-11       Impact factor: 5.103

View more
  2 in total

1.  Lentiviral Gene Therapy for Familial Hemophagocytic Lymphohistiocytosis Type 3, Caused by UNC13D Genetic Defects.

Authors:  Sarah E Takushi; Na Yoon Paik; Andrew Fedanov; Chengyu Prince; Christopher B Doering; H Trent Spencer; Shanmuganathan Chandrakasan
Journal:  Hum Gene Ther       Date:  2020-06       Impact factor: 5.695

2.  Cholesterol Supplementation During Production Increases the Infectivity of Retroviral and Lentiviral Vectors Pseudotyped with the Vesicular Stomatitis Virus Glycoprotein (VSV-G).

Authors:  Yong Chen; Christopher J Ott; Kay Townsend; Papasani Subbaiah; Ashok Aiyar; William M Miller
Journal:  Biochem Eng J       Date:  2009-05-15       Impact factor: 3.978

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.